Pharmaceuticals, Biotech & Life Sciences Brands · Advertiser / Brand
AbbVie
Biopharmaceutical company developing and commercialising prescription medicines.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- AbbVie Inc.
- Entity type
- COMPANY
- Founded
- 2012
- Headquarters
- United States
- Company size
- >5,000
- Market cluster / sector
- Pharmaceuticals, Biotech & Life Sciences Brands
- Market role
- Advertiser / Brand
- Ticker
- ABBV
- Official website
- news.abbvie.com
What AbbVie does
AbbVie creates value by researching, developing, manufacturing and commercialising prescription medicines protected by regulatory approvals, intellectual property and brand equity. Revenue is generated primarily through selling approved therapies into healthcare distribution and provider channels, supported by large-scale commercial, medical and regulatory operations.
Category differentiation
AbbVie is a pharmaceutical manufacturer, not an adtech, martech or media platform. It should not be confused with healthcare software vendors or advertising businesses serving pharma brands.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
AbbVie is a large US-headquartered biopharmaceutical company founded in 2012 and operating as a public company. It develops, manufactures and commercialises prescription medicines, generating revenue from the sale of branded therapies through healthcare channels. Its direct commercial customers are typically healthcare systems, hospitals, clinics, pharmacies, distributors and other institutional healthcare buyers rather than end consumers. Based on the information provided, AbbVie should be understood as a healthcare manufacturer and commercial pharmaceutical business, not as a media, software or advertising company.
Company news briefing
Briefing updated:
Building upon its acquisition of Apogee Therapeutics, AbbVie has further advanced its clinical and regulatory pipeline. Recent developments include FDA approval for JUVMO in Parkinson's disease, positive Phase 3 results for etentamig in multiple myeloma and atogepant in menstrual migraine, alongside real-world effectiveness data for VRAYLAR. Furthermore, AbbVie joined the Antibody Developability Consortium to leverage federated AI for drug discovery, submitted an EMA application for subcutaneous SKYRIZI in Crohn's disease, and showcased new lung cancer pipeline data.
Business model & monetisation
AbbVie’s monetisation model is primarily product sales of prescription medicines, with revenue realised through healthcare distribution, provider and pharmacy channels. The supplied data does not specify pricing mechanics, therapeutic areas, licensing income or service-based revenue, so the observable model is best described as commercial pharmaceutical sales.
Products & capabilities
No products with linked sources are available in this view.
POLARIS7 WORKSPACE
Go deeper on AbbVie and its market context
Access extended corporate structures, historical M&A and partnership links, technical footprint data, and automated Watchlist briefings grounded in primary sources.
- Corporate & subsidiary hierarchy
- Competitor & partner network
- Automated Watchlist briefings
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across AbbVie's competitive landscape.
Global pharmaceutical company selling medicines and vaccines.
Large public healthcare manufacturer and commercial products company.
Pharmaceutical group selling generics, specialty medicines and consumer healthcare.
Public pharmaceutical company developing, manufacturing and marketing human medicines.
Global medical device and healthcare technology manufacturer.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
AbbVie Director Jennifer L. Davis Resigns Following Align Technology CEO Appointment
Leadership & People · Recorded impact score: 1.8/5
On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc., notified the Board of Directors of her intent to resign, effective November 2, 2026. The resignation is directly attributable to her recent appointment as Chief Executive Officer at Align Technology, Inc. The company explicitly confirmed that her departure does not stem from any dispute or disagreement regarding AbbVie's operations, policies, or practices.
- Class II Director Jennifer L. Davis notified AbbVie of her resignation on October 28, 2026, effective November 2, 2026.
- The resignation was prompted by her appointment as CEO of Align Technology, Inc.
AbbVie Expands Board of Directors to Thirteen Members with Appointment of Dr. John M. Carethers
Leadership & People · Recorded impact score: 2.2/5
On October 14, 2026, AbbVie Inc. enlarged its Board of Directors from twelve to thirteen members and appointed Dr. John M. Carethers as an independent Class II director. Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and brings previous corporate governance experience as a director at Avantor, Inc. Alongside his board appointment, Dr. Carethers has been named to AbbVie's Public Policy and Sustainability Committee, receiving standard independent director compensation.
- AbbVie expanded its Board of Directors from 12 to 13 members effective October 14, 2026.
- Dr. John M. Carethers was appointed as an independent Class II director and joins the Public Policy and Sustainability Committee.
AbbVie Updates Q3 and FY 2026 EPS Guidance Following $216M Acquired IPR&D Expense
M&A & Corporate Finance · Recorded impact score: 3.5/5
AbbVie Inc. announced that its reported GAAP and adjusted non-GAAP results for the third quarter of 2026 will include $216 million of pre-tax acquired in-process research and development (IPR&D) and milestones expense. This charge represents an unfavorable impact of approximately $0.11 per diluted share on both GAAP and adjusted non-GAAP bases. Because AbbVie does not model unannounced collaboration, licensing, or asset acquisition expenses into its forecasts, the company updated its guidance to factor in this Q3 charge. Consequently, AbbVie revised its Q3 2026 adjusted diluted EPS guidance to $3.73–$3.77 and updated its full-year 2026 adjusted diluted EPS guidance range to $13.76–$13.96.
- Pre-tax acquired IPR&D and milestones expense for Q3 2026 is expected to be $216 million.
- The pre-tax expense represents an unfavorable EPS impact of $0.11 per diluted share for both GAAP and adjusted non-GAAP metrics.
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Product & Platform Launch · Recorded impact score: 4/5
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
Product & Platform Launch
The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease. The approval is based on Phase 3 TEMPO data showing significant improvements in daily functioning, increased "on" time without troublesome dyskinesia, and a favorable safety profile. AbbVie expects to make JUVMO available to U.S. patients in October 2026.
- The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease.
- The approval was supported by Phase 3 TEMPO clinical trial data (TEMPO-1, TEMPO-2, TEMPO-3, and TEMPO-4).
Explore company relationships
Questions about AbbVie
What is AbbVie?
AbbVie is a US-based public biopharmaceutical company that develops, manufactures and commercialises prescription medicines.
Who uses AbbVie?
Its products are used within the healthcare ecosystem, with commercial relationships typically involving hospitals, clinics, pharmacies, distributors and other institutional healthcare buyers.
How does AbbVie make money?
AbbVie primarily makes money by selling branded prescription medicines through healthcare and pharmaceutical distribution channels.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
5 publicly documented primary sources and citations linked across the market graph.
Start with a company or market. Track what changes.
Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.
AbbVie
Open extended company details, ownership links, and automated signal monitoring in Polaris7.
